Brind.

Neurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.

2 reports, 1 independent Updated Oct 20

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Neurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.

Who's involved

What this event is mainly about

FDA

How it developed

Newest first. Tap a step to see who reported it.

Oct 20Neurogene shared clinical data at the ESGCT congress.1 source
- finanznachrichten.de
Jul 1Neurogene received FDA agreement for a registrational trial of its Rett syndrome gene therapy.

Keep exploring

The entities involved

FDA
- The FDA approved Miplyffa for the treatment of Niemann-Pick disease.00:55
- iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Fri 23:50

Coverage

Newest first; wire copies grouped

Oct 20finanznachrichten.de
Jul 1Unknown outlet